Terlipressin in paediatric hepatorenal syndrome-acute kidney injury (HRS-AKI)
Authors:
Open Access
- 19 February 2026
- journal article
- review article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (10) , 1-10
Abstract
Children with chronic liver disease are at increased risk of acute kidney injury (AKI), which could be non-hepatorenal syndrome AKI (non-HRS-AKI) or hepatorenal syndrome AKI (HRS-AKI). Approximately 5–10% of these children develop HRS-AKI. In this cohort, portal hypertension leads to splanchnic vasodilatation, reduced mean arterial pressure, and compensatory renal arteriolar vasoconstriction. The reduction of mean arterial pressure and renal vasoconstriction reduces renal perfusion, causing functional renal failure and AKI (acute kidney injury). HRS-AKI may be precipitated by sepsis or inflammation, which may impact cardiac function in patients with cirrhotic cardiomyopathy. While liver transplantation remains curative, adult randomised controlled trials have demonstrated that treatment with terlipressin can potentially reverse HRS-AKI. Limited paediatric studies also suggest terlipressin may also be effective in children, though effects on mortality remain unexplored. In this review, we explore the prevalence and pathophysiology of HRS-AKI in paediatric liver disease, summarise evidence from adult trials supporting terlipressin use, highlight cautions and contraindications associated with its use in adults and children, and propose principles for its safe prescription. Additionally, we outline future research priorities, including the potential role of renal biomarkers in managing this high-risk population. Graphical AbstractKeywords
This publication has 62 references indexed in Scilit:
- Diagnostic and prognostic performance of urinary neutrophil gelatinase‐associated lipocalin in patients with cirrhosis and acute kidney injuryHepatology, 2023
- Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled studyHepatology, 2016
- Renal Replacement Therapy in Infants and Children With Hepatorenal Syndrome Awaiting Liver Transplantation: a Case-Control StudyLiver Transplantation, 2014
- Evaluation of the Pediatric Patient for Liver Transplantation: 2014 Practice Guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and NutritionHepatology, 2014
- Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhageHepatology, 2014
- Impact of the etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus hepatorenal syndromeLiver Transplantation, 2012
- Predictors of Response to Therapy With Terlipressin and Albumin in Patients With Cirrhosis and Type 1 Hepatorenal SyndromeHepatology, 2009
- Nitration of cardiac proteins is associated with abnormal cardiac chronotropic responses in rats with biliary cirrhosis†Hepatology, 2006
- Cystatin C, an easy and reliable marker for assessment of renal dysfunction in children with liver disease and after liver transplantationLiver Transplantation, 2005
- Hemodynamic Effects of Glucagon in Portal HypertensionHepatology, 1990